Filtered By:
Specialty: Research
Condition: Thrombosis
This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 312 results found since Jan 2013.
Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19
CONCLUSION: NVAF patients with COVID-19 who discontinued apixaban had a higher risk of hospitalization and thrombotic events vs. those who continued apixaban, with no significant difference in bleeding-related hospitalization.PMID:36000258 | DOI:10.1080/03007995.2022.2112871
Source: Current Medical Research and Opinion - August 24, 2022 Category: Research Authors: Steven Deitelzweig Julia Zhu Jenny Jiang Xuemei Luo Allison Keshishian Mauricio Ferri Lisa Rosenblatt Patricia Schuler Cynthia Gutierrez Amol D Dhamane Source Type: research
Payer Formulary exclusions of apixaban: how patients respond and potential implications
Curr Med Res Opin. 2022 Sep 26:1-10. doi: 10.1080/03007995.2022.2128189. Online ahead of print.ABSTRACTIn recent years, U.S. payers have increased usage of formulary exclusions as a means to help manage costs. Earlier this year, one of the largest pharmacy benefit managers in the country added Eliquis (apixaban), the most widely used anticoagulant, to its list of excluded medicines from its formulary, raising concerns by physicians and patients. In this commentary, we examine the potential impacts of formulary exclusion of a drug like apixaban-a treatment for patients with atrial fibrillation and venous thromboembolism to ...
Source: Current Medical Research and Opinion - September 27, 2022 Category: Research Authors: Steven Deitelzweig Emi Terasawa Amiee Kang Nipun Atreja Dionne M Hines Ahmed Noman Xuemei Luo Source Type: research
Mechanisms of COVID-19-induced cerebellitis
Curr Med Res Opin. 2022 Oct 28:1-25. doi: 10.1080/03007995.2022.2141963. Online ahead of print.ABSTRACTThe COVID-19 pandemic caused by SARS-CoV2 has raised several important health concerns, not least increased mortality and morbidity. SARS-CoV2 can infect the central nervous system via hematogenous or transneuronal routes, acting through different receptors including ACE2, DPP4 and neuropilin 1- and cause several issues, include the focus here, cerebellitis. The cerebellum is an essential part of the CNS located adjacent to the brainstem with a complex micro and macroscopic structure. The cerebellum plays several physiolo...
Source: Current Medical Research and Opinion - October 28, 2022 Category: Research Authors: Mohammad Banazadeh Sepehr Olangian-Tehrani Melika Sharifi Mohammadreza Malek-Ahmadi Farhad Nikzad Nooria Doozandeh-Nargesi Alireza Mohammadi Gary J Stephens Mohammad Shabani Source Type: research
Clinical Outcomes of Extracranial Carotid Artery-Related Stroke Eligible for Mechanical Reperfusion on Top of Per-Guidelines Thrombolytic Therapy: Analysis from a 6-Month Consecutive Patient Sample in 2 Centers
Med Sci Monit. 2022 Dec 1;28:e938549. doi: 10.12659/MSM.938549.NO ABSTRACTPMID:36451526 | DOI:10.12659/MSM.938549
Source: Medical Science Monitor - December 1, 2022 Category: Research Authors: Karolina Dzierwa Magdalena Knapik Łukasz Tekieli Adam Mazurek Ma łgorzata Urbańczyk-Zawadzka Artur Klecha Tomasz Kowalczyk Teresa Ko źmik Łukasz Wiewiórka Pawe ł Banyś Ewa W ęglarz Justyna Stefaniak Rafa ł T Nizankowski Iris Q Grunwald Piotr Mus Source Type: research
Therapeutic effect of antithrombotic drug combinations in patients with atrial fibrillation undergoing percutaneous coronary intervention for coronary heart disease: a meta-analysis
CONCLUSIONS: DAT with NOACs has a higher safety profile against bleeding in patients with atrial fibrillation after PCI. DAT with VKAs was similar to TAT in terms of antithrombotic effect and incidence of bleeding.PMID:36628223 | PMC:PMC9827321
Source: American Journal of Translational Research - January 11, 2023 Category: Research Authors: Huabin He Xifeng Xiao Xiangyang Yuan Jianhai Chen Source Type: research
